1968
DOI: 10.1001/archinte.1968.03640060063012
|View full text |Cite
|
Sign up to set email alerts
|

Successful Metyrapone Therapy of the Ectopic ACTH Syndrome

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

1978
1978
2020
2020

Publication Types

Select...
3
2

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(3 citation statements)
references
References 10 publications
0
3
0
Order By: Relevance
“…Metyrapone is a specific inhibitor of 11-hydroxylase (202). Its efficacy in EAS has been known for almost 5 decades (203,204,205,206) and has been confirmed in more recent studies (113,201,202). Given its short half-life and pharmacokinetics, metyrapone needs to be administered in three of four daily fractions.…”
Section: (B) Specific Treatments: Personalized Medicinementioning
confidence: 99%
See 2 more Smart Citations
“…Metyrapone is a specific inhibitor of 11-hydroxylase (202). Its efficacy in EAS has been known for almost 5 decades (203,204,205,206) and has been confirmed in more recent studies (113,201,202). Given its short half-life and pharmacokinetics, metyrapone needs to be administered in three of four daily fractions.…”
Section: (B) Specific Treatments: Personalized Medicinementioning
confidence: 99%
“…Given its short half-life and pharmacokinetics, metyrapone needs to be administered in three of four daily fractions. The dosage depends on the degree of hypercortisolism and may range from 1500 to 6000 mg/d (202,203,205,206). When used at adequate doses, it is a very effective drug in the short term, leading to a drastic fall in urinary cortisol within 24 to 72 h (113,201,202).…”
Section: (B) Specific Treatments: Personalized Medicinementioning
confidence: 99%
See 1 more Smart Citation